ReviewArchives of biochemistry and biophysics2018
Myeloperoxidase in the inflamed colon: A novel target for treating inflammatory bowel disease.
Review in Archives of biochemistry and biophysics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 108 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
108 citing papers in PubMed, 2 syntheses or guidelines pooled it, 262 citations in OpenAlex.
- Salivary Alterations of Myeloperoxidase in Patients with Systemic Diseases: A Systematic Review.International journal of molecular sciences · 2023Pooled it
- Bioactive Compounds from Kefir and Their Potential Benefits on Health: A Systematic Review and Meta-Analysis.Oxidative medicine and cellular longevity · 2021Pooled it
- Modulating immune toxicity in ulcerative colitis using a small molecule RAB27A inhibitor.Inflammatory bowel diseases · 2026Article
- Analysis of multiplexed SERS-based lateral flow assays: turning qualitative into quantitative for inflammatory bowel disease monitoring.The Analyst · 2026Article
- Mucin armoured diethylaminoethyl-dextran cloaked rebamipide based oral nanoformulation for the therapy of inflammatory bowel disease.Materials today. Bio · 2026Article
- Prevalence and Correlates of Environmental Enteric Dysfunction Among Young Children in Bangladesh.Maternal & child nutrition · 2026Article
- An Edible HAdvanced healthcare materials · 2026Article
- Preparation and Characterization of Rice Bran Protein Hydrolysates Enhanced via Alcalase andNutrients · 2026Article
- Genome-Wide Dissection of the Neutrophil-to-Lymphocyte Ratio Uncovers Polygenic Determinants Linked to Inflammatory Gastrointestinal Disorder Susceptibility.Biomedicines · 2026Article
- Rhamnogalacturonan rich fractions isolated fromNutrition research and practice · 2026Article
- Bifidobacterium breve B2798 and Its Heat-Killed Cells Alleviate Inflammation in Rats with DSS Model by Modulating Gut Microbiota.Probiotics and antimicrobial proteins · 2026Article
- Oral colon targeted curcumin-based nanocomposite inulin hydrogel for alleviating intestinal inflammation and dysbiosis.Journal of nanobiotechnology · 2026Article
- Alleviating Effects ofInternational journal of molecular sciences · 2026Article
- MODULATING OXIDATIVE STRESS AND INFLAMMATION: SODIUM BUTYRATE'S THERAPEUTIC PROMISE IN EXPERIMENTAL COLITIS.Arquivos de gastroenterologia · 2026Article
- Baitong Decoction Ameliorates DSS-Induced Colitis via Modulation of STING and JAK/STAT Pathways.ACS omega · 2025Article
- Plasma Calprotectin and Myeloperoxidase as Biomarkers in Inflammatory Bowel Disease.Inflammatory bowel diseases · 2025Article
- From Cytokines to Biomarkers: Mapping the Immunopathology of Inflammatory Bowel Disease.Cells · 2025Review
- Curcumin for inflammatory bowel disease therapy: advances in mechanisms, clinical applications, and drug delivery.Archives of pharmacal research · 2025Review
- Article
- Magnetite Micro/Nanorobots for Efficient Targeted Alleviation of Inflammatory Bowel Disease.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
48 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inflammatory bowel disease (IBD) is a debilitating disorder involving inflammation of the gastrointestinal tract. The incidence of IBD is increasing worldwide. Immunological responses in the gastrointestinal (GI) tract to altered gut microbiota, mucosal injury and loss of intestinal epithelial cell function all contribute to a complex mechanism underlying IBD pathogenesis. Immune cell infiltration, particularly neutrophils, is a histological feature of IBD. This innate immune response is aimed at resolving intestinal damage however, neutrophils and monocytes that are recruited and accumulate in the GI wall, participate in IBD pathogenesis by producing inflammatory cytokines and soluble mediators such as reactive oxygen species (ROS; one- and two-electron oxidants). Unregulated ROS production in host tissue is linked to oxidative damage and inflammation and may potentiate mucosal injury. Neutrophil-myeloperoxidase (MPO) is an abundant granule enzyme that catalyses production of potent ROS; biomarkers of oxidative damage (and MPO protein) are increased in the mucosa of patients with IBD. Targeting MPO may mitigate oxidative damage to host tissue and ensuing inflammation. Here we identify mechanisms by which MPO activity perpetuates inflammation and contributes to host-tissue injury in patients with IBD and discuss MPO as a potential therapeutic target to protect the colon from inflammatory injury.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.